Alnylam Pharmaceuticals (ALNY) earnings, Jul 30, 2026: EPS +337%, stock −28.3%
In brief
Alnylam Pharmaceuticals reported on Jul 30, 2026. Earnings per share changed +337% year over year, 25.8% below the estimate; revenue +67%. The stock opened with a −21.5% gap and closed the day −28.3% (Jul 30, 2026). The stock is now 67.3% below its 52-week high, −63.9% over 12 months. Next report: Feb 18, 2027.
EPS vs estimate−25.8%
EPS, YoY+337%
Revenue, YoY+67%
Gap · day−21.5% · −28.3%
EPS growth by quarter, YoY
Price reaction to earnings
| Report | Gap | Day |
|---|---|---|
| Jul 30, 2026 | −21.5% | −28.3% |
Next-quarter estimates, ratings and the ALNY chart are in the terminal.
Open the terminalFAQ
When is Alnylam Pharmaceuticals's next earnings report?
Feb 18, 2027. The date comes from daily data and is corrected if the company moves it.
How did Alnylam Pharmaceuticals stock react to the report?
Opening gap −21.5%, day's result −28.3%.
Did Alnylam Pharmaceuticals's earnings grow?
Earnings per share rose 337% year over year.
What is an earnings gap?
The jump between the close before and the open after the report. A big gap up often means large buyers are revaluing the company.